Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR

Authors

Jennifer L. Taylor-Cousar, National Jewish Health
Manu Jain, Northwestern University
Tara Lynn Barto, Baylor College of Medicine
Tarik Haddad, Tampa General Hospital
Jeffrey Atkinson, Washington University School of Medicine in St. Louis
Simon Tian, Vertex Pharmaceuticals Incorporated
Rui Tang, Vertex Pharmaceuticals Incorporated
Gautham Marigowda, Vertex Pharmaceuticals Incorporated
David Waltz, Vertex Pharmaceuticals Incorporated
Joseph Pilewski, University of Pittsburgh
VH14-809-106 Investigator Group

Journal

Journal of Cystic Fibrosis

Publication Date

2018

Volume

17

Issue

2

Inclusive Pages

228-235

Document Type

Open Access Publication

DOI

10.1016/j.jcf.2017.09.012

Rights and Permissions

Taylor-Cousar JL, Jain M, Barto TL, Haddad T, Atkinson J, Tian S, Tang R, Marigowda G, Waltz D, Pilewski J (2018) Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. Journal of Cystic Fibrosis, 17(2): 228-235. https://doi.org/10.1016/j.jcf.2017.09.012 © 2017 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Taylor-Cousar, Jennifer L.; Jain, Manu; Barto, Tara Lynn; Haddad, Tarik; Atkinson, Jeffrey; Tian, Simon; Tang, Rui; Marigowda, Gautham; Waltz, David; Pilewski, Joseph; and VH14-809-106 Investigator Group, "Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR." Journal of Cystic Fibrosis. 17, 2. 228-235. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6675